Simulated microgravity-mediated reversion of murine lymphoma immune evasion

No human has returned to the moon since the end of the Apollo program 47 years ago, however, new missions are planned for an orbital outpost. Space radiation and the potential for cancer remain as important issues to the future of human space exploration. While improved shield technologies and prote...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports Vol. 9; no. 1; pp. 14623 - 11
Main Authors: Bradley, Jillian H., Barwick, Shannon, Horn, Gillian Q., Ullrich, Elizabeth, Best, Brianna, Arnold, Jennifer P., Gregg, Randal K.
Format: Journal Article
Language:English
Published: London Nature Publishing Group UK 10-10-2019
Nature Publishing Group
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:No human has returned to the moon since the end of the Apollo program 47 years ago, however, new missions are planned for an orbital outpost. Space radiation and the potential for cancer remain as important issues to the future of human space exploration. While improved shield technologies and protective biologicals are under development, little is known concerning the interaction between cancer cells and host immunity in microgravity. As a hallmark of cancer, tumor cells employ mechanisms of immune evasion to avoid elimination by protective CD4 + and CD8 + T cells. We showed that a murine lymphoma was able to produce a soluble factor that inhibited the function of dendritic cells in activating the CD4 + T cells. Culture of the lymphoma cells in simulated microgravity (SMG), and not Static conditions, restored the CD4 + T cell response and augmented CD8 + T cell-mediated destruction of the cancer cells in vitro and in vivo . Thus, SMG impaired the mechanism of tumor escape and rendered the cancer cells more susceptible to T cell-mediated elimination. The stress of microgravity may expose the most critical components of a tumor’s escape mechanism for astronaut protection and the generation of new cancer therapeutics for patients on Earth.
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-019-51106-y